Brendan Guercio, Genitourinary Medical Oncologist at University of Rochester Medical Center, shared Uromigos ‘s post on X, adding:
“Fantastic and fun summary of the post-EV/pembrolizumab landscape in advanced urothelial carcinoma by David Aggen of Memorial Sloan Kettering Cancer Center for Uromigos.
Platinum chemo retains modest activity, but hope for a better future post-EVP clearly lies with the novel and exciting ADC’s, T-cell engagers, radioligands and targeted therapies explained below. The future for our patients is starting to look brighter!”
Uromigos shared:
“What’s the next step after EV + pembrolizumab in metastatic bladder cancer?
David Aggen explores second-line treatment options, from platinum-based chemotherapy and biomarker-directed therapies to emerging ADCs and clinical trials.”
You can also read: